BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Sirtuins and novel PTMs in cancer
DTSTART:20161205T110000
DTEND:20161205T123000
DTSTAMP:20260930T215039Z
UID:78da13e614175032364c52202b99244222320b5c376cdaa461b9cc21
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Hening Lin Dr. Hening Lin obtained his BS degree in chem
 istry from Tsinghua University in Beijing\, China in 1998\, and his PhD de
 gree in bio-organic chemistry in Dr. Virginia Cornish’s laboratory from 
 Columbia University in New York City in 2003. After his postdoctoral studi
 es with Dr. Christopher Walsh at Harvard Medical School\, he became a facu
 lty member in Department of Chemistry and Chemical Biology\, Cornell Unive
 rsity in Ithaca\, New York in 2006. He was promoted to associate professor
  with tenure in 2012 and to full professor in 2013. His laboratory studies
  the chemistry\, biology\, and application of enzymes\, in particular NAD+
 -consuming enzymes\, such as sirtuins and PARPs. Dr. Lin was a Jane Coffin
  Childs Fellow while at Harvard Medical School. His awards include the Cam
 ille and Henry Dreyfus New Faculty Award and CAPA Distinguished Junior and
  Senior Faculty Awards\, the 2014 ACS Pfizer Award in Enzyme Chemistry. He
  was selected as a Howard Hughes Medical Institute Investigator in 2015.\n
 Sirtuins\, which are known as nicotinamide adenine dinucleotide (NAD)-dep
 endent deacetylases. They regulate aging\, transcription\, and metabolism\
 , and are considered important targets for treating several human diseases
 . There are seven sirtuins in humans\, SIRT1-7. Four of them (SIRT4-7) hav
 e very weak deacetylase activity\, which have caused many confusions and d
 ebates in the biological community. My laboratory has recently discovered 
 several novel enzymatic activities\, such as desuccinylation and defatty-a
 cylation\, for several sirtuins with no robust deacetylase activity. This 
 have led to the identification of previously unknown protein posttranslati
 onal modifications (PTMs) and revealed new regulatory mechanisms of biolog
 y. Furthermore\, this finding has enabled us to develop compounds that can
  inhibit particular sirtuins selectively. Some of the selective sirtuins i
 nhibitors can kill cancer cells in cell culture and inhibit tumor formatio
 n in mouse models at least partly via the regulation of c-Myc and Ras. The
  roles of sirtuins and the new PTMs in cancer are being elucidated.
LOCATION:BCH 2218 https://plan.epfl.ch/?room==BCH%202218
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR